Globally, colorectal cancer is the third most common type of cancer making up about 10% of all cancer cases. In 2012 there were 1.4 million new cases and 694,000 deaths from colorectal cancer1. The 5-year survival rates in the United States are around 65%.
Colorectal cancer typically starts with a benign tumour
Colorectal cancer typically starts with a benign tumour, often in the form of a polyp, which over time becomes cancerous1. Treatment options are depending on the stage of the disease, overall health and preferences of the patient2. Standard treatments include surgery, chemotherapy, radiotherapy or a combination3.
1. Colorectal cancer,
Wikipedia, last edited January 2018
2. Current standards and new trends in the primary treatment of colorectal cancer,
Stein, Alexander et al., European Journal of Cancer , Volume 47 , S312 - S314, Sep. 2011
3. Colon Cancer Treatment (PDQ®) – Patient Version,
National Cancer Institute, updated December 2017
- Cyramza (ramucirumab)
by Lilly for€2,364.00
- Lonsurf (trifluridine/tipiracil)
by Les Laboratoires Servier for Colorectal Cancer€813.96
- Opdivo (nivolumab)
by Bristol-Myers Squibb Pharma EEIG for Urothelial Carcinoma, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer€497.04